Detalhe da pesquisa
1.
Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.
J Infect Dis
; 222(4): 628-636, 2020 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31681963
2.
Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
Clin Infect Dis
; 63(8): 1113-1121, 2016 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27439527
3.
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial.
EClinicalMedicine
; 58: 101912, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36969345
4.
Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.
PLoS One
; 16(8): e0255250, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415933
5.
The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial.
PLoS One
; 15(1): e0228003, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31999753